After Tacti-003’s controlled cohorts fail, Immutep plays up single-arm data in PD-L1 non-expressers.

Predictably Tacti-003 fails, but funding is secured – from investors, not a partner.

April will see the first big scientific meeting of the year, and could herald important data from Immutep and GSK.

Results with eftilagimod alpha in first-line head and neck cancer threaten to cloud partnering prospects.